The pharmacodynamics and safety of progesterone

Piette, Paul C.M.

doi:10.1016/j.bpobgyn.2020.06.002

Cited by 35 publications

(30 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The population prevalence of breast cancer in women aged 40 to 64 years is 0.3% [28]. The results of the REPLENISH trial are consistent with the findings of previously published studies [9,29] indicating that MHT based on oestradiol and progesterone does not increase the risk of breast cancer. Breast tenderness during therapy with E2/P4-1/100 was reported by 10.8% of patients, but only in 1.4% of cases it led to the discontinuation of therapy [21].…”

Section: Safety Profilesupporting

confidence: 79%

Position Statement by Experts of the Polish Menopause and Andropause Society on menopausal hormone therapy with an oral combination drug containing oestradiol 1 mg and progesterone 100 mg

Bińkowska

Jakiel

Paszkowski

et al. 2021

View full text Add to dashboard Cite

Section: Safety Profilesupporting

confidence: 79%

Position Statement by Experts of the Polish Menopause and Andropause Society on menopausal hormone therapy with an oral combination drug containing oestradiol 1 mg and progesterone 100 mg

Bińkowska

Jakiel

Paszkowski

et al. 2021

View full text Add to dashboard Cite

“…Overall, progesterone shows numerous functions on the myometrium: it has been shown to induce high levels of cyclic adenosine mono phosphate (cAMP) and time-dependent stimulation of nitric oxide synthetase (NOS), as well as to inhibit the myometrial gap junctions’ (channels made of connexin 43) formation. Natural progesterone (P4) and its metabolites promote uterine quiescence both through interactions between nuclear and membrane P4 receptors and by inducing low levels of the inflammatory prostaglandins (via cyclooxygenase), oxytocin and intracellular calcium [ 29 , 30 , 31 , 32 ].…”

Section: Progesterone: Biochemical “Identikit” and Rationale For Usementioning

confidence: 99%

“…There is a need for future follow-up studies on prenatal progesterone administration and its effects in offspring beyond early childhood. Therefore, nowadays, the safety profile of natural progesterone is quite confirmed, while the one of progestogens is raising many issues of concern (particularly relating to the use of 17-OHPC and dydrogesterone as alternatives to natural progesterone) [ 32 , 35 , 60 ].…”

Section: Progesterone Safety Profilementioning

confidence: 99%

Prevention of Preterm Birth with Progesterone

Renzo

Tosto

Цибизова

et al. 2021

JCM

View full text Add to dashboard Cite

Gestational age at birth is a critical factor for perinatal and adulthood outcomes, and even for transgenerational conditions’ effects. Preterm birth (PTB) (prematurity) is still the main determinant for infant mortality and morbidity leading cause of infant morbidity and mortality. Unfortunately, preterm birth (PTB) is a relevant public health issue worldwide and the global PTB rate is around 11%. The premature activation of labor is underlined by complex mechanisms, with a multifactorial origin influenced by numerous known and probably unknown triggers. The possible mechanisms involved in a too early labor activation have been partially explained, and involve chemokines, receptors, and imbalanced inflammatory paths. Strategies for the early detection and prevention of this obstetric condition were proposed in clinical settings with interesting results. Progesterone has been demonstrated to have a key role in PTB prevention, showing several positive effects, such as lower prostaglandin synthesis, the inhibition of cervical stromal degradation, modulating the inflammatory response, reducing gap junction formation, and decreasing myometrial activation. The available scientific knowledge, data and recommendations address multiple current areas of debate regarding the use of progesterone in multifetal gestation, including different formulations, doses and routes of administration and its safety profile in pregnancy.

show abstract

“…Taken together, this suggests that progesterone may offer a promising avenue for further investigation as an addiction treatment for women. Benefits of progesterone and its metabolites as a treatment include limited evidence of addiction liability, low cost and high accessibility in a range of formulations, with the option of repurposing widely available hormone‐based contraceptives 90,91 . Further, there is already an established academic and clinical knowledge base on the safety and tolerability profile of synthetic progestins at doses utilised for contraceptive purposes, with growing data on improved psychiatric side‐effect profile associated with natural progestins 91 .…”

Section: Discussionmentioning

confidence: 99%

A systematic review of the effect of ovarian sex hormones on stimulant use in females

et al. 2021

View full text Add to dashboard Cite

Stimulant use disorder is associated with significant global health burden. Despite evidence for sex differences in the development and maintenance of stimulant use disorder, few studies have focused on mechanisms underpinning distinct trajectories in females versus males, including the effect of the ovarian sex hormones estrogen and progesterone. This review aimed to identify and synthesise the existing preclinical and clinical literature on the effect of ovarian sex hormones on stimulant consumption in females. A systematic search of peer‐reviewed literature identified 1593 articles, screened using the following inclusion criteria: (1) adult female humans or animals, (2) using stimulant drugs, (3) ovarian sex hormones were administered exogenously OR were measured in a validated manner and (4) with stimulant consumption as an outcome measure. A total of 50 studies (3 clinical and 47 preclinical) met inclusion criteria. High‐estrogen (low progesterone) phases of the menstrual/estrus cycle were associated with increased stimulant use in preclinical studies, while there were no clinical studies examining estrogen and stimulant consumption. Consistent preclinical evidence supported progesterone use reducing stimulant consumption, which was also identified in one clinical study. The review was limited by inconsistent data reporting across studies and different protocols across preclinical laboratory paradigms. Importantly, almost all studies examined cocaine use, with impact on methamphetamine use a significant gap in the existing evidence. Given the safety and tolerability profile of progesterone, further research is urgently needed to address this gap, to explore the potential therapeutic utility of progesterone as a treatment for stimulant use disorder.

show abstract

The pharmacodynamics and safety of progesterone

Cited by 35 publications

References 106 publications

Position Statement by Experts of the Polish Menopause and Andropause Society on menopausal hormone therapy with an oral combination drug containing oestradiol 1 mg and progesterone 100 mg

Position Statement by Experts of the Polish Menopause and Andropause Society on menopausal hormone therapy with an oral combination drug containing oestradiol 1 mg and progesterone 100 mg

Prevention of Preterm Birth with Progesterone

A systematic review of the effect of ovarian sex hormones on stimulant use in females

Contact Info

Product

Resources

About